Euroapi (EPA: EAPI), a French company and a spinoff from Sanofi established in 2022, has announced plans to reduce production of 13 active pharmaceutical ingredients (APIs), as reported by Nikkei News. This strategic decision will lead to the divestment of its manufacturing facilities located in Brindisi, Italy, and Haverhill, UK, with an expected completion date set for 2027.
Citing a company spokesperson, the decision was attributed to “decreasing or stagnant markets and increasing competition from Asian manufacturers.” Euroapi’s production reduction includes APIs for antipyretics, diuretics, anti-infectives, and other complex-chemistry products. The move is expected to benefit Chinese pharmaceutical manufacturers such as Shandong Xinhua Pharmaceutical, China Grand Pharmaceutical and Healthcare Holding, Hebei Jiheng (Group) Pharmaceutical, and Zhejiang Haisen Pharmaceutical. This development aligns with a broader trend of European API manufacturing being challenged by the low-cost competition from Asia. Industry association Pro Generika notes a significant shift from Europe producing two-thirds of APIs at the end of the 1990s to now importing two-thirds from Asia, primarily from manufacturers in China and India.- Flcube.com
